UPCC 17821 The Delayed Intervention and Surveillance For Small Renal Masses (DISSRM) Registry (DISSRM)

Study on Monitoring and Immediate Treatment for Small Kidney Tumors

Enrolling By Invitation
18 years - 100 years
All
Phase N/A
600 participants needed
1 Location

Brief description of study

Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, <=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.

Detailed description of study

All patients are offered active surveillance or immediate intervention, as applicable, prior to being offered consent for the DISSRM Registry. All patients are enrolled and followed prospectively. Surveillance patients are followed per protocol with serial imaging, blood work and quality of life questionnaires. Intervention patients are followed at the discretion of the attending surgeon with serial QOL appointments/questionnaires.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Kidney Neoplasm
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria:

  • Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months.
  • Age ≥ 18 and able to read, understand and sign informed consent.
  • Must be willing to adhere to the treatment algorithm and time constraints therein.

Exclusion Criteria:

  • Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.

The purpose of this study is to investigate the safety and effectiveness of active surveillance compared to immediate intervention for patients with small kidney tumors. This study will compare two approaches: monitoring the tumor over time or treating it right away.

Participants in the study will be divided into two study arms. Those in the active surveillance arm will undergo regular imaging tests, blood work, and complete quality of life questionnaires. Participants in the intervention arm will receive treatment as decided by their surgeon and also complete quality of life questionnaires.

  • Who can participate: Adults aged 18 and older with a kidney tumor 4 centimeters or smaller found in the last 6 months may participate. Participants must be able to read, understand, and sign an informed consent form. They should be willing to follow the study's treatment plan and timeline.
  • Study details: Participants will either be monitored with regular medical check-ups and tests or receive immediate treatment for their kidney tumor. They will also complete questionnaires about their quality of life.
Updated on 28 Jul 2026. Study ID: 21-1334
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator